If these results are replicated in chondrosarcoma xenograft studies and are eventually used in humans, reducing the concentration of PARP inhibitors may help avoid side effects including common hematologic toxicities that often lead to dose modification, interruption, and discontinuation [24]. Here, PARP1 is linked to chondrosarcoma.